Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gargi D Basu

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Acta Medica Academica|February 17, 2023
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the GroupSemir Vranic, Gargi D Basu, David W Hall, et al.
Breast Cancer Research : BCR|July 1, 2005
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cellsGargi D Basu, Latha B Pathangey, Teresa L Tinder, et al.
Case Reports in Oncology|April 24, 2023
Identification of a Novel <i>NRG1</i> Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case ReportSarah G Mitchell, Gargi D Basu, Bree Eaton, et al.
Molecular Cancer Research : MCR|November 25, 2004
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancerGargi D Basu, Latha B Pathangey, Teresa L Tinder, et al.
Breast Disease|February 3, 2005
Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer modelPinku Mukherjee, Teresa L Tinder, Gargi D Basu, et al.
Oncotarget|November 22, 2014
Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 casesZoran Gatalica, Sherri Z Millis, Semir Vranic, et al.
Cancer Research|March 3, 2007
Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplificationRiina Kuuselo, Kimmo Savinainen, David O Azorsa, et al.
Gynecologic Oncology|August 20, 2010
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cellsShilpi Arora, Kristen M Bisanz, Lourdes A Peralta, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2006
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDOGargi D Basu, Teresa L Tinder, Judy M Bradley, et al.
Breast Cancer Research : BCR|December 13, 2006
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cellsGargi D Basu, Winnie S Liang, Dietrich A Stephan, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Acta Medica Academica|February 17, 2023
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the GroupSemir Vranic, Gargi D Basu, David W Hall, et al.
Breast Cancer Research : BCR|July 1, 2005
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cellsGargi D Basu, Latha B Pathangey, Teresa L Tinder, et al.
Case Reports in Oncology|April 24, 2023
Identification of a Novel <i>NRG1</i> Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case ReportSarah G Mitchell, Gargi D Basu, Bree Eaton, et al.
Molecular Cancer Research : MCR|November 25, 2004
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancerGargi D Basu, Latha B Pathangey, Teresa L Tinder, et al.
Breast Disease|February 3, 2005
Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer modelPinku Mukherjee, Teresa L Tinder, Gargi D Basu, et al.
Oncotarget|November 22, 2014
Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 casesZoran Gatalica, Sherri Z Millis, Semir Vranic, et al.
Cancer Research|March 3, 2007
Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplificationRiina Kuuselo, Kimmo Savinainen, David O Azorsa, et al.
Gynecologic Oncology|August 20, 2010
RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cellsShilpi Arora, Kristen M Bisanz, Lourdes A Peralta, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2006
Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDOGargi D Basu, Teresa L Tinder, Judy M Bradley, et al.
Breast Cancer Research : BCR|December 13, 2006
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cellsGargi D Basu, Winnie S Liang, Dietrich A Stephan, et al.
Pageof 3